Must have hemoglobin (Hgb) ? . g/dL within days prior to randomization. Must not have required transfusion of red blood cells within week of baseline Hgb assessment. Patients with Hgb > . g/dl (transfusion allowed) Additional Laboratory Requirements ANC ?. x /L Hgb ? g/dL(transfusion permitted) Platelet count ?. x /L Obtained within days prior to registration: Hemoglobin (Hgb) >= g/dL (without erythrocyte stimulating agent or transfusion within days of screening) Hgb > . (transfusion allowed) Hemoglobin (HgB) > g/dL. Must not have required transfusion of red blood cells within week of baseline Hgb assessment. Hemoglobin (Hgb) >= g/dL (with/without transfusion) Hgb > . (transfusion allowed) Hemoglobin (Hgb) >= g/dL (acceptable to reach via transfusion) obtained within days prior to initiating study treatment. Hemoglobin (Hgb) < mg/dl, per PI discretion if thought to be related to underlying myeloma Hemoglobin (Hgb) >= g/dL (more than hours post-completion of blood transfusion) Hemoglobin (Hgb) >= g/dL (in absence of blood transfusion). Within weeks of day : Hemoglobin (HgB) >= . gr/dL independent of transfusion Hemoglobin (Hgb) ? g/dL obtained ? days prior to randomization; patient may receive transfusion as needed Hemoglobin (Hgb) >= g/dL or >= . mmol/L without (w/o) transfusion within days of assessment. Hemoglobin (Hgb) >= g/dL; (last transfusion cannot be within days of trial initiation) Hemoglobin (Hgb) >= g/dL (use of transfusion to reach this threshold prior to study initiation is acceptable) EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Hemoglobin (Hgb) < mg/dl (transfusion permitted to achieve this) EXCLUSION CRITERIA FOR TNBC: Hgb < mg/dl (transfusion permitted to achieve this) PRIOR TO CELL PROCUREMENT: Hemoglobin (Hgb) ? . g/dL (transfusion independent for weeks prior to enrollment) Within days prior to study entry: Hemoglobin (Hgb) > . g/dL (with or without transfusion) TREATMENT: Hgb > . (transfusion allowed) Hemoglobin (HgB) > . g/dL; NOTE: subjects may not have had a transfusion within days of registration Within days of study drug(s) initiation: Hemoglobin (Hgb) >= g/dL with no blood transfusion in the past days. Hemoglobin (Hgb) >= g/dl (transfusion acceptable) HGB ? g/dl and not transfusion dependent Hemoglobin (HgB) > g/dL (acceptable to reach this by transfusion) Within days of study start: Hemoglobin (Hgb) >= g/dL (may transfuse if clinically indicated) Hemoglobin (Hgb) > g/dL (can be achieved with transfusion) Hemoglobin (Hgb) >= gm/dL (transfusion independent) Hemoglobin (Hgb) >= . g/dL (no red blood cell [RBC] transfusion within past days)\r\n* Hgb >= . g/dL for patients with anemia associated disease Hemoglobin (Hgb) >= g/dL (which may be post transfusion) Hemoglobin (Hgb) >= . g/dL (transfusion before treatment is allowable if more than days prior to study start) Hemoglobin (Hgb) >= . g/dL ( g/L) without blood transfusion within days Hemoglobin (Hgb) >= g/dL (use of transfusion to reach this threshold prior to study initiation is acceptable) Hemoglobin (Hgb) >= mg/dL (which may be post transfusion) Hemoglobin (Hgb) >= g/dL may be supported by transfusion and/or hematopoetic growth factors Hemoglobin (Hgb) >= . g/dL (transfusion allowed), within days of registration Hemoglobin (Hgb) >= . g/dL (transfusion or erythropoietin-like substances not permitted prior to baseline evaluation) Hemoglobin (Hgb) ? . g/dL within days prior to randomization. Must not have required transfusion within week of baseline Hgb assessment. Hgb > . g/dl (without transfusion within days) Required prior to infusion of ATLCAR.CD cells: Hgb >= g/dL without transfusion support over preceding days Hemoglobin (Hgb) > . g/dL with no blood transfusion in the past days Hemoglobin (hgb) ? . g/dL (may be supported with transfusion) Hemoglobin (Hgb) >= g/dL ( g/L); < g/dL (< g/L) is acceptable if Hgb is corrected to >= g/dL ( g/L) as by growth factor or transfusion prior to PET scan, obtained within days prior to PET scan